NVIDIA has released a safety platform for robotics developers and updated its simulation, AI, and autonomous vehicle ...

Wherever you live in South Florida, the flooding you see right now is likely to get worse in the years ahead – despite ...

In today’s fast-moving business world, true innovation stands out—not just in what’s created, but in how it's delivered, scaled, and sustained. Through bold strategy, purpose-driven leadership, and an ...

Even as Honda Motor globally fine-tunes its clean mobility strategy with a renewed emphasis on hybrids alongside electric ...

As part of the deal, Sanofi is acquiring Blueprint’s rare immunology disease medication Ayvakit/Ayvakat, which has been approved in the U.S. and the EU for advanced and indolent systemic ...

The Blueprint deal comes after Sanofi made an unsuccessful play in 2022 for another rare disease specialist, Horizon Therapeutics. In that case, Amgen took the prize with its $27.8 billion offer.

Europe can't win the AI race with cash alone. Nvidia sparks momentum—but only bold reforms will make EU a true AI power. Here ...

Europe can't win the AI race with cash alone. Nvidia sparks momentum—but only bold reforms will make EU a true AI power. Here ...

Sanofi will acquire Blueprint Medicines for up to $9.5 billion, gaining Ayvakit and a promising immunology pipeline, including BLU-808 and elenestinib.

Call of Duty is giving away a free Weapon Blueprint called Star Traveler to all Black Ops 6 and Warzone players. It is for the LR 7.62 Sniper Rifle , which is equipped with a unique set of ...

The two companies said on Monday that Sanofi would initially pay $129.00 per share in cash, or around $9.1 billion. Blueprint shares jumped 27% to $128.74 in premarket trade.

"The most realistic scenario could very well be Orlando opting for minor trades as well as declining various options to gain access to the full $14.1 million midlevel exception.